Summary Background Disease-modifying antirheumatic drugs (DMARDs) are standard first-line therapy for psoriatic arthritis (PsA). Observational studies suggest earlier initiation is associated with superior minimal disease activity (MDA) attainment, yet the economic and health implications of treatment timing remain unc...
Sabrina Hundal, Julian Cappelli, Savanah Haidar et al.· The Lancet Regional Health -...· 0 citations
Objective
To compare demographic and clinical characteristics of patients who did and did not meet the magnetic resonance imaging (MRI) axial inflammation eligibility criteria for the STAR study.
Methods
STAR is a phase 4, randomized, placebo-controlled trial of guselkumab, a selective interleukin-23p19-subunit inhib...
X. Baraliakos, P. Bird, A. Deodhar et al.· Journal of Psoriasis and Pso...· 0 citations
Elevated levels of interferons (IFN) are a hallmark of Systemic Lupus Erythematosus (SLE) and are linked to disease flares, but the precise mechanisms underlying this remain unclear. We examined the association between IFN-stimulated proteins (ISPs) and immune changes in flaring and quiescent SLE patients at single...
Zoha Faheem, Giselle M. Boukhaled, Carol Nassar et al.· Frontiers in Immunology· 0 citations
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease associated with a severe morbidity and mortality. Around 70% of SLE patients follow a relapse-remitting pattern of disease characterized by flares of disease activity, followed by prolonged periods of disease quiescence. Memory CD4+ T cell subsets h...
C. Nassar, Rene Quevedo, M. Ciudad et al.· Journal of Rheumatology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
